Drug Profile
Bortezomib - BioXcel
Alternative Names: BXCL 101Latest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator BioXcel Corporation
- Class Amides; Anti-ischaemics; Antineoplastics; Antirheumatics; Boronic acids; Pyrazines; Small molecules; Vascular disorder therapies
- Mechanism of Action Apoprotein stimulants; Immunomodulators; Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Neurofibromatosis 2
Highest Development Phases
- No development reported Neurofibromatosis 2
Most Recent Events
- 16 Mar 2021 No development reported - Phase-I/II for Neurofibromatosis 2 (unspecified route)
- 23 May 2018 Phase-I/II clinical trials in Neurofibromatosis 2 (unspecified route) (BioXcel pipeline, May 2018)
- 11 May 2017 Chemical structure information added